Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
12
05
2020
accepted:
26
06
2020
pubmed:
12
7
2020
medline:
25
9
2020
entrez:
12
7
2020
Statut:
ppublish
Résumé
Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date
Identifiants
pubmed: 32651581
doi: 10.1038/s41591-020-0998-x
pii: 10.1038/s41591-020-0998-x
pmc: PMC8194108
mid: NIHMS1705843
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1422-1427Subventions
Organisme : NIAID NIH HHS
ID : 75N93019C00074
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI157155
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93019C00062
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR028106
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024975
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI110483
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI141993
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000445
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007151
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI095202
Pays : United States
Commentaires et corrections
Type : UpdateOf
Références
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
pubmed: 32015507
pmcid: 32015507
doi: 10.1038/s41586-020-2012-7
Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).
pubmed: 31978945
pmcid: 31978945
doi: 10.1056/NEJMoa2001017
Sui, J. et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl Acad. Sci. USA 101, 2536–2541 (2004).
pubmed: 14983044
doi: 10.1073/pnas.0307140101
ter Meulen, J. et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363, 2139–2141 (2004).
pubmed: 15220038
pmcid: 7112500
doi: 10.1016/S0140-6736(04)16506-9
ter Meulen, J. et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 3, e237 (2006).
pubmed: 16796401
pmcid: 1483912
doi: 10.1371/journal.pmed.0030237
Zhu, Z. et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl Acad. Sci. USA 104, 12123–12128 (2007).
pubmed: 17620608
doi: 10.1073/pnas.0701000104
Rockx, B. et al. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J. Virol. 82, 3220–3235 (2008).
pubmed: 18199635
pmcid: 2268459
doi: 10.1128/JVI.02377-07
Chen, Z. et al. Human neutralizing monoclonal antibody inhibition of Middle East respiratory syndrome coronavirus replication in the common marmoset. J. Infect. Dis. 215, 1807–1815 (2017).
pubmed: 28472421
pmcid: 7107363
doi: 10.1093/infdis/jix209
Choi, J. H. et al. Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. PLoS ONE 15, e0232757 (2020).
pubmed: 32384116
pmcid: 7209324
doi: 10.1371/journal.pone.0232757
Niu, P. et al. Ultrapotent human neutralizing antibody repertoires against Middle East respiratory syndrome coronavirus from a recovered patient. J. Infect. Dis. 218, 1249–1260 (2018).
pubmed: 29846635
pmcid: 7107445
doi: 10.1093/infdis/jiy311
Wang, L., et al. Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the Middle East respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape. J. Virol. 92, e02002-17 (2018).
Wang, N. et al. Structural definition of a neutralization-sensitive epitope on the MERS-CoV S1-NTD. Cell Rep. 28, e3396 (2019).
Zhang, S. et al. Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein. Cell Rep. 24, 441–452 (2018).
pubmed: 29996104
pmcid: 7104183
doi: 10.1016/j.celrep.2018.06.041
Corti, D. et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc. Natl Acad. Sci. USA 112, 10473–10478 (2015).
pubmed: 26216974
doi: 10.1073/pnas.1510199112
Jiang, L. et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci. Transl. Med. 6, 234ra259 (2014).
doi: 10.1126/scitranslmed.3008140
Tang, X. C. et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc. Natl Acad. Sci. USA 111, E2018–E2026 (2014).
pubmed: 24778221
doi: 10.1073/pnas.1402074111
Ying, T. et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J. Virol. 88, 7796–7805 (2014).
pubmed: 24789777
pmcid: 4097770
doi: 10.1128/JVI.00912-14
Jiang, S., Hillyer, C. & Du, L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 41, 355–359 (2020).
pubmed: 32249063
pmcid: 7129017
doi: 10.1016/j.it.2020.03.007
Gilchuk, P. et al. Integrated technology platform for accelerated discovery of antiviral antibody therapeutics. Nat. Biomed. Eng. (in the press).
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
pubmed: 32075877
pmcid: 7164637
doi: 10.1126/science.abb2507
Holshue, M. L. et al. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med. 382, 929–936 (2020).
pubmed: 32004427
pmcid: 7092802
doi: 10.1056/NEJMoa2001191
Gilchuk, P. et al. Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus meutralization. Immunity 52, e312 (2020).
doi: 10.1016/j.immuni.2020.01.001
Soto, C. et al. High frequency of shared clonotypes in human B cell receptor repertoires. Nature 566, 398–402 (2019).
pubmed: 30760926
pmcid: 6949180
doi: 10.1038/s41586-019-0934-8
Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181–193 (2011).
pubmed: 21220454
pmcid: 3023136
doi: 10.1084/jem.20101352
Case, J. B. et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe https://doi.org/10.1016/j.chom.2020.06.021 (2020).
Rogers, T. F. et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. Science https://doi.org/10.1126/science.abc7520 (2020).
Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. Nature https://doi.org/10.1038/s41586-020-2456-9 (2020).
Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science eabc5902 (2020).
Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell https://doi.org/10.1016/j.cell.2020.05.025 (2020).
Shi, R. et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature https://doi.org/10.1038/s41586-020-2381-y (2020).
Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274–1278 (2020).
Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature https://doi.org/10.1038/s41586-020-2380-z (2020).
Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science https://doi.org/10.1126/science.abc7424 (2020).
Williamson, L. E. et al. Early human B cell response to Ebola virus in four U.S. survivors of infection. J. Virol. 93, e01439-18 (2019).
Davis, C. W. et al. Longitudinal analysis of the human B cell response to Ebola virus infection. Cell 177, e1517 (2019).
doi: 10.1016/j.cell.2019.04.036
Zost, S. J. et al. Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals. Nature (in the press).
Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, e286 (2020).
doi: 10.1016/j.cell.2020.02.058
Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020).
pubmed: 32225176
doi: 10.1038/s41586-020-2180-5
Mukherjee, S. et al. Enhancing dengue virus maturation using a stable furin over-expressing cell line. Virology 497, 33–40 (2016).
pubmed: 27420797
pmcid: 5502530
doi: 10.1016/j.virol.2016.06.022
Ohi, M., Li, Y., Cheng, Y. & Walz, T. Negative staining and image classification—powerful tools in modern electron microscopy. Biol. Proced. Online 6, 23–34 (2004).
pubmed: 15103397
pmcid: 389902
doi: 10.1251/bpo70
Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152, 36–51 (2005).
pubmed: 16182563
doi: 10.1016/j.jsb.2005.07.007
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
doi: 10.1038/nmeth.4169
Bepler, T., Noble, A. J. & Berger, B. Topaz-Denoise: general deep denoising models for cryoEM. Preprint at https://doi.org/10.1101/838920 (2019).
Nguyen, D. C. et al. Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion. Nat. Commun. 9, 3698 (2018).
pubmed: 30209264
pmcid: 6135805
doi: 10.1038/s41467-018-05853-7
Guthmiller, J. J., Dugan, H. L., Neu, K. E., Lan, L. Y. & Wilson, P. C. An efficient method to generate monoclonal antibodies from human B cells. Methods Mol. Biol. 1904, 109–145 (2019).
pubmed: 30539468
doi: 10.1007/978-1-4939-8958-4_5
Soto C. F. J. et al. PyIR: A scalable wrapper for processing billions of immunoglobulin and T cell receptor sequences using IgBLAST. BMC Bioinformatics (in the press).
Chng, J. et al. Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells. MAbs 7, 403–412 (2015).
pubmed: 25621616
pmcid: 4622431
doi: 10.1080/19420862.2015.1008351
Scobey, T. et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA 110, 16157–16162 (2013).
pubmed: 24043791
doi: 10.1073/pnas.1311542110
Yount, B. et al. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA 100, 12995–13000 (2003).
pubmed: 14569023
doi: 10.1073/pnas.1735582100